Ampersand Capital Partners to acquire the Huntsville, Alabama manufacturing facility and reagent supply business of Nektar Therapeutics for $90m.

Ampersand Capital Partners, a Boston-based private equity firm, agreed to acquire the Huntsville, Alabama manufacturing facility and reagent supply business of Nektar Therapeutics, a global biotechnology company, for $90m. "This sale streamlines Nektar's operations as we continue to focus on the future success and clinical advancement of rezpegaldesleukin and our other antibody-based immunology pipeline assets, including our TNFR2 antibody and bispecific programs," Howard W. Robin, Nektar Therapeutics President and CEO.